|
Stories from the dialysis comunity across the globe.
|
|
New clinical trial investigates novel treatment for challenging ... - Rancho Santa Fe Review |
 |
 |
Rancho Santa Fe Review
In people with hypertension, the renal nerves are hyperactive. This leads to increased blood pressure and contributes to heart, kidney and blood vessel damage.
Vanderbilt Heart and Vascular Institute tests new therapy for
|
|
|
Groundbreaking Held for New Dialysis Center - Du Quoin Evening Call |
|
|
|
Cut Cefepime Dose in Kidney Disease FDA Says - MedPage Today |
|
|
|
By John Gever, Senior Editor, MedPage Today
The antibiotic cefepime (Maxipime) may cause a specific type of seizure in patients with kidney impairment when doses are not reduced appropriately, the FDA warned.
Nearly 60 cases of nonconvulsive status epilepticus have been reported to the FDA since cefepime was approved in 1996, the agency said in a drug safety communication.
In 58 of the 59 incidents, the patients had renal impairment, and, in 56, label recommendations for lowered doses were not followed. Most of the seizures occurred in patients older than 65.
Sixteen of the patients died, including two in whom the seizures might have contributed to the fatal outcome, according to the FDA. But the agency stopped short of concluding that failure to adjust cefepime dosages was a cause of any of the deaths.
The FDA has ordered that cefepime's label be revised to highlight the seizure risk in patients with renal impairment (those with creatinine clearance of ?60 mL/min) and reiterating the importance of dosage adjustments in such patients.
Clinicians with patients who have seizures while receiving cefepime should consider stopping the drug or reducing the dose in patients with renal impairment, the agency advised.
Add Your Knowledge ™
Take Posttest
John Gever
Senior Editor
John Gever, Senior Editor, has covered biomedicine and medical technology for 30 years. He holds a B.S. from the University of Michigan and an M.S. from Boston University. Now based in Pittsburgh, he is the daily assignment editor for MedPage Today as well as general factotum on the reporting side. Go Pirates/Penguins/Steelers!
|
|
|
AAKP and Baxter Offer Scholarships for Upcoming Meeting - Renal Business Today |
|
|
|
TAMPA, Fla.—The American Association of Kidney Patients (AAKP) and Baxter Healthcare are pleased to announce 50 patient scholarships to attend the 39th Annual AAKP National Patient Meeting, August 9-11, 2012 at the Grand Hyatt Atlanta in Georgia.
The scholarships cover attendees meeting registration entrance fees.
“We realize that people are weighing every expense very carefully,” stated AAKP Executive Director Karen Ryals. “The current economy has an influence on whether someone can attend a conference, even one as important as the AAKP Patient Meeting. We hope these scholarships will make the decision to come to the meeting easier for some people.”
The AAKP Patient Meeting is the largest event of its kind, bringing together patients, family members and health care professionals for learning, networking and fun! The meeting is divided into three categories—chronic kidney disease (CKD)/pre-dialysis; end-stage renal disease (ESRD)/dialysis; and kidney transplantation. Attendees are welcome to attend sessions outside their modality.
For more information on available scholarships and to access the online application, please visit www.aakp.org/events/convention/2012-convention/Meeting-Scholarship. As part of the scholarship application process, applicants are also asked to submit a 100 word essay on how attending the AAKP Patient Meeting will help them to become the leader of their health care team. Complete applications must be in the AAKP office by Friday, July 13, 2013. AAKP would like to thank Baxter Healthcare for its support of the AAKP Patient Education Scholarships.
|
|
Considerable variability found between 25-D assays. |
|
|
|
EurekAlert: The researchers performed statistical analysis (linear regression and bias analysis) of the results. In 40 percent of the Architect-tested specimens and in 48 percent of the Centaur2-tested specimens, the results were at least 25 percent too high or 25 percent too low, compared with the third technique, Holmes reported. The maximum recommended allowable error for 25-hydroxyvitamin D tests is plus or minus 25 percent, and he stated that the sizes of the observed errors ranged from ? to +80 percent.
|
|
|
|
|
<< Start < Prev 511 512 513 514 515 516 517 518 519 520 Next > End >>
|
|
Page 517 of 4210 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
